1. Home
  2. MESO vs HOV Comparison

MESO vs HOV Comparison

Compare MESO & HOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • HOV
  • Stock Information
  • Founded
  • MESO 2004
  • HOV 1959
  • Country
  • MESO Australia
  • HOV United States
  • Employees
  • MESO N/A
  • HOV N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • HOV Homebuilding
  • Sector
  • MESO Health Care
  • HOV Consumer Discretionary
  • Exchange
  • MESO Nasdaq
  • HOV Nasdaq
  • Market Cap
  • MESO 1.1B
  • HOV 1.3B
  • IPO Year
  • MESO N/A
  • HOV N/A
  • Fundamental
  • Price
  • MESO $10.18
  • HOV $175.51
  • Analyst Decision
  • MESO Strong Buy
  • HOV Hold
  • Analyst Count
  • MESO 4
  • HOV 1
  • Target Price
  • MESO $11.50
  • HOV $155.00
  • AVG Volume (30 Days)
  • MESO 215.6K
  • HOV 63.6K
  • Earning Date
  • MESO 08-28-2024
  • HOV 12-03-2024
  • Dividend Yield
  • MESO N/A
  • HOV N/A
  • EPS Growth
  • MESO N/A
  • HOV 48.22
  • EPS
  • MESO N/A
  • HOV 31.75
  • Revenue
  • MESO $5,902,000.00
  • HOV $2,912,312,000.00
  • Revenue This Year
  • MESO $66.05
  • HOV N/A
  • Revenue Next Year
  • MESO $348.27
  • HOV N/A
  • P/E Ratio
  • MESO N/A
  • HOV $5.42
  • Revenue Growth
  • MESO N/A
  • HOV 5.68
  • 52 Week Low
  • MESO $1.61
  • HOV $86.61
  • 52 Week High
  • MESO $12.18
  • HOV $240.34
  • Technical
  • Relative Strength Index (RSI)
  • MESO 54.91
  • HOV 45.94
  • Support Level
  • MESO $10.00
  • HOV $164.70
  • Resistance Level
  • MESO $10.98
  • HOV $188.60
  • Average True Range (ATR)
  • MESO 0.59
  • HOV 8.94
  • MACD
  • MESO 0.06
  • HOV 0.40
  • Stochastic Oscillator
  • MESO 47.92
  • HOV 42.73

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About HOV Hovnanian Enterprises Inc.

Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.

Share on Social Networks: